P soriasis affects between 0%-2.15% of children in Europe and Asia. 1 Previous studies demonstrated a consistently increased risk for cardiovascular comorbidities among adults with psoriasis, including ischemic heart disease, peripheral vascular disease, atherosclerosis, diabetes, hypertension, dyslipidemia, obesity, and metabolic syndrome. 2 Less is known about cardiovascular risk factors and events in childhood psoriasis.
In a recent meta-analysis using 7 studies including 965 children, the metabolic and cardiovascular risks of children with psoriasis were assessed. 3 This study found significantly higher rates of metabolic syndrome in 3 studies (with only 60 children), lower high-density lipoprotein cholesterol levels in 6 of 7 studies, and higher fasting glucose levels in 4 studies (with only 40 children), but no significant differences in triglyceride levels, waist circumference, or blood pressure. 3 These studies were limited by insufficient power to detect metabolic and cardiovascular risk.
We hypothesized that children with psoriasis are at higher risk for cardiovascular risk factors and even cardiovascular disease. Demographic factors (eg, age, sex, and race/ethnicity) are associated with differential risk of both psoriasis and cardiovascular disease. We hypothesized that cardiovascular risk in childhood psoriasis is influenced by demographic factors. In this study, we examined the association between psoriasis and cardiovascular risk factors and disease in a nationwide cohort of hospitalized children.
METHODS
We analyzed data from the 2002-2012 Nationwide Inpatient Sample (NIS) provided by the Healthcare Cost and Utilization Project from the Agency for Healthcare Research and Quality. Each year of NIS data contains an approximately 20% stratified representative sample of all hospitalizations in the United States. Sample weights were created by NIS that factored the complex sampling design and were used to provide representative estimates of discharges across the United States. Data were deidentified and no attempts were made to identify individuals in the database. Patient consent was not obtained as the databases were received deidentified. All parties with access were compliant to Healthcare Cost and Utilization Project's formal data use agreement. The study was approved by the institutional review board at Northwestern University.
Identification of psoriasis and comorbidities
Psoriasis and comorbidities were determined through the use of the International Classification of Disease Ninth Clinical Modification (ICD-9-CM) and Clinical Classification Software codes provided by the NIS for each patient discharged (Table I) . A previous study validated the use of the discharge diagnosis code 696.1 in the inpatient setting for the study of psoriasis. 4, 5 The control group included all pediatric patients without a diagnosis of psoriasis, yielding a representative cohort of hospitalized children in the United States. Newborn infants were excluded from the cohort.
Statistics
All data analyses and statistical processes were performed using SURVEY procedures in SAS version 9.4 (SAS Institute Inc, Cary, NC). Analyses were limited to ages 0-17 years. Summary statistics were generated. Adjusted P values are presented, with values #.05 considered significant.
Survey weighted binary logistic regression models with strata and cluster analysis were constructed to determine the association of psoriasis (independent variable) with various comorbidities (dependent variables). Crude odds ratios and 95% confidence intervals are presented. Multivariate logistic regression models included age (continuous); sex (male, female); and race/ethnicity (white, nonwhite) as covariates. Regression models were also stratified by race/ethnicity (white, black, Hispanic, multiracial/other); sex (male, female); and age (0-9 years, 10-17 years). In models stratified by race/ethnicity, covariates included age and sex. In models stratified by sex, covariates included age and race/ethnicity. In models stratified by age, covariates included sex and race/ethnicity. Multivariate regression models were also constructed that included age (continuous); sex (male, female); and race/ethnicity (white, nonwhite) as above, as well as obesity (yes, no); hypertension (yes, no); and diabetes (yes, no). Adjusted odds ratios and 95% confidence intervals are presented.
RESULTS
Overall, there were 4,884,448 hospital discharges captured in the NIS data set between 2002 and 2012 for children (ages 0-17 years). There were 126 admissions with a primary and 1380 admissions with a secondary diagnosis of pediatric psoriasis, which was equivalent to a weighted prevalence of 25.8 and 287.4 admissions per 1 million persons, respectively. Pediatric inpatients with a diagnosis of psoriasis were 47.5% male, 64.9% white, 11.9% black, and 14.2% Hispanic.
Cardiovascular comorbidities
In bivariate survey logistic regression models, 6 of 10 cardiovascular comorbidities analyzed were significantly associated with pediatric psoriasis (Table II) . Obesity was the most common comorbidity in childhood psoriasis, occurring in 7.5%
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compared with only 1.4% of those without psoriasis (survey logistic regression). Psoriasis was associated with higher rates of hypertension, diabetes, arrhythmia, heart conduction disorders, and composite lipid abnormality.
In multivariate regression models adjusting for age, sex, and race/ethnicity, the associations with pediatric psoriasis remained significant in 4 of 6 comorbidities: obesity, hypertension, diabetes, and arrhythmia. In addition, psoriasis was significantly associated with valvular heart disease in multivariate models, despite no association in bivariate analyses (Table II) .
Because of the lack of or infrequency of occurrences among children, an association between psoriasis and the following could not be determined: congestive heart failure, pulmonary circulatory disorder, diabetes mellitus with chronic complications, atrial fibrillation, peripheral vascular disease, pulmonary hypertension, myocardial infarction, coronary artery disease, cardiomyopathy, supraventricular arrhythmia, sinoatrial node dysfunction, ventricular tachycardia, myocarditis, endocardial fibroelastosis, history of unspecified circulatory disease, personal history of transient ischemic attack and cerebral infarction, chronic ischemic heart disease, other cerebrovascular disorders, subendocardial infarction, carotid artery occlusion, cardiac arrest, and peripheral and visceral atherosclerosis.
Stratified models by sociodemographics
To determine which subsets of hospitalized psoriasis patients are at highest risk for cardiovascular comorbidities, stratified analyses were performed by demographics for comorbidities that were significant in either bivariate or multivariate analyses and had sufficient frequencies (Table III) . The association between obesity and psoriasis was significant among Hispanics, blacks, whites, and marginally significant among multiracial/other. The association between diabetes and psoriasis was strongest among blacks, followed by Hispanics and whites. Similarly, the association between psoriasis and hypertension was strongest among blacks, followed by Hispanics and whites. Arrhythmia was only significantly associated with psoriasis among races/ethnicities categorized as other and not among whites or Hispanics. Valvular heart disease was significantly associated with psoriasis only among whites. Heart conduction disorder was marginally significantly associated with psoriasis among whites. Composite lipid abnormalities were associated with psoriasis among Hispanics.
Boys with psoriasis were significantly more likely to have obesity, diabetes, and hypertension but not arrhythmia. Girls with psoriasis had higher odds of having obesity, diabetes, hypertension, and arrhythmia.
The associations of obesity, diabetes, and hypertension with psoriasis were stronger among children aged 0-9 years than among children aged 10-17 years. Psoriasis was marginally associated with arrhythmia and significantly associated with valvular heart disease only among children aged 10-17 years but not 0-9 years. Psoriasis was associated with heart conduction disorder but not with composite lipid abnormality among children aged 10-17 years.
The associations of obesity, diabetes, and hypertension with psoriasis were significant among children living in areas with household incomes both below and above the national median and among children with health insurance. There was insufficient power to stratify models by insurance status.
Overlap of cardiovascular comorbidities
The majority of pediatric psoriasis patients who had arrhythmia, valvular heart disease, heart conduction disorder, and composite lipid abnormality did not have obesity, hypertension, or diabetes (Table IV) .
DISCUSSION
This study found higher odds of multiple cardiovascular comorbidities among pediatric inpatients with psoriasis. Pediatric psoriasis was associated with higher odds of cardiovascular risk factors, including obesity, diabetes, hypertension, and lipid abnormalities, as well as arrhythmias, valvular heart disease, and heart conduction disorder. The cardiovascular comorbidities occurred at greatest frequency among adolescents aged 10-17 years. However, the relative increase of odds of cardiovascular comorbidities was highest among children aged 0-9 years. This is likely due to lower rates of cardiovascular comorbidities among younger children without psoriasis (controls). There were significantly increased odds of cardiovascular risk factors across racial/ethnic groups. The strongest effect sizes for cardiovascular risk were observed among black and Hispanic children. Black and Hispanic patients might have higher cardiovascular risk, even in the absence of psoriasis. However, psoriasis was associated with increased cardiovascular risk in multivariate models controlling for race/ethnicity, as well as in bivariate models stratified by race/ ethnicity. There were no apparent sex differences for any comorbidity.
These data might have important clinical ramifications. Children with psoriasis could benefit from early and more frequent surveillance of cardiovascular risk, in order to initiate lifestyle interventions or Our results are consistent with previous studies. [6] [7] [8] A German study of 1.3 million nonselected individuals from a health insurance database indicated that children with a diagnosis of psoriasis had increased rates of hyperlipidemia, obesity, hypertension, and diabetes. 6 A case-control study of adolescents aged 10-18 years found that psoriasis was associated with higher body mass index, waist circumference, systolic blood pressure, plasma glucose, and higher levels of high-sensitivity C-reactive protein than controls. 7 A pediatric case-control study (age range 5-15 years) found that psoriasis was associated with higher body mass index, waist circumference, waist-to-height ratio, blood pressure, and prevalence of metabolic syndrome. 8 The highest odds of obesity, diabetes, and hypertension occurred among black and Hispanic children with psoriasis. Obesity, diabetes, and hypertension were increased among children aged 0-9 and 10-17 years, with highest odds for children aged 0-9 years. Psoriasis was marginally associated with arrhythmia and significantly associated with valvular heart disease and heart conduction disorder among children aged 10-17 years. These stratified analyses require careful interpretation. Although 1506 cases of pediatric psoriasis were included in these analyses, many of the cardiovascular comorbidities are rare outcomes. Thus, there was reduced statistical power for the subset analyses. There was little overlap of obesity, hypertension, and diabetes with arrhythmia, valvular heart disease, heart conduction disorder, and composite lipid abnormality. Children with psoriasis were more likely to have 1 cardiovascular comorbidity but not multiple. Phenotypical differences of psoriasis and patient characteristics might differentially impact risk and type of cardiovascular comorbidity. Finally, the typical cardiovascular risk factors might not account for the excess risk of other cardiovascular comorbidities observed.
The mechanism of increased cardiovascular risk in pediatric psoriasis has not been thoroughly explored. Adult studies showed that systemic inflammatory responses are activated in both mild and severe psoriasis, resulting in imbalances of neutrophil activation products and their inhibitors. 9 Others suggest that abnormal C-reactive protein and a2-macroglobulin plasma activity among people with psoriasis might confer increased cardiovascular risk. 10 Elevated levels of plasma osteopontin are associated with psoriasis, as well as hypertension, diabetes, and severity of coronary artery disease. 11 Adolescents with psoriasis had higher blood levels of lipids, including mean total cholesterol, triglycerides, and low-density lipoproteins. 12 Abnormal changes in plasma lipid composition, in conjunction with increased oxidative stress and decreased antioxidant capacity, are linked to increased cardiovascular disease among patients with psoriasis. 13 Regardless of the mechanism, there is biologic plausibility for a direct relationship between having psoriasis and cardiovascular risk.
The strengths of this study include analysis of a large-scale, nationally representative, all-payer data set of all hospitalizations over a period of 11 years. The use of ICD-9-CM codes for identifying psoriasis in the inpatient setting was previously validated. 5 Despite the large sample size overall, there were low frequencies of children with psoriasis and some comorbidities. Patients analyzed were from an inpatient setting, which might not be generalizable to all children with psoriasis. Hospitalized children with psoriasis likely have more severe disease and receive more intensive treatment, and thus do not represent the entire spectrum of psoriasis. It might be the case that children with mild psoriasis seen as outpatients have minimal or no increased cardiovascular risk. On the other hand, cardiovascular comorbidities might be greater than observed, considering underreporting of dermatologic conditions has been observed in adults when patients are admitted for acute comorbidities, eg, myocardial infarction.
14 All entries within the NIS were single inpatient admissions rather than complete health records for individual patients. Dates of diagnosis of psoriasis and comorbidities were not available, precluding assessment of temporal relationships between psoriasis and comorbidities. Family history, psoriasis treatment, and treatment effects on comorbidities were unavailable in NIS.
Early-onset cardiovascular risk factors might predispose a person to cardiovascular events later in adulthood. However, one study showed that childhood-onset psoriasis was not associated with increased cardiovascular comorbidities in adulthood. 15 Some studies have shown that systemic therapy for psoriasis decreased biomarkers of cardiovascular risk, 16 suggesting that excess cardiovascular risk might be modifiable with improved control of the skin disease or other strategies. Further study is required to determine the effect of cardiovascular comorbidities on pediatric psoriasis. 
